Posts – Page 103 – Safe Biologics

Proceed with caution on creating ‘biosimilar’ drugs

November 15, 2010

Dr. Edward Treadwell, Department of Internal Medicine at the Brody School of Medicine at East Carolina University in Greenville, N.C.
Buffalo News

Americans elected a new Congress on Nov. 2, but the voting booth wasn’t the only place where critical issues were at stake that day. Away from the spotlight of election news coverage, a committee of the federal Food and Drug Administration held a hearing in a Washington suburb on the future of biologic drugs, perhaps the most promising health care breakthrough of our lifetime.

The new battle over prescription drugs

November 11, 2010

Dr. Edward Treadwell, Department of Internal Medicine at the Brody School of Medicine at East Carolina University in Greenville, N.C.
Tampa Tribune

Away from the spotlight of election news coverage, a committee of the U.S. Food and Drug Administration (FDA) held a hearing in a Washington suburb on the future of biologic drugs, perhaps the most promising health care breakthrough of our lifetime.

Biologics: Are Unsafe Drugs an ‘Acceptable Risk?’ FDA Should Say ‘No!’

November 7, 2010

John Horton, President, LegitScript
Huffington Post

For cancer patients, what is the “acceptable risk” that a drug will pose safety risks or won’t work properly? That’s one of the thorny questions addressed by the FDA last week in a two-day, open-to-the-public meeting about “biosimilar” drugs — second-generation versions of drugs made from living organisms, or “biologics.”

Understanding the challenges of next generation medicine

November 1, 2010

Dr. Donald Palmisano, Former head of the AMA
Times Picayune

The English writer Aldous Huxley once said that humanity has “an absolute and infinite capacity for taking things for granted.” I think about that as I consider the remarkable achievements we’ve made in medicine over the past century from discoveries like penicillin and insulin to the ability to transplant an organ.

Clinical Trials Key to Keeping New Drugs Safe

October 29, 2010

Dr. Gary Puckrein, President and CEO, National Minority Quality Forum
Opposing Views

Patient safety is a core component of our medical system. In order to assure that physicians are prescribing the best and safest treatments

Clinical Trials Key to Keeping New Drugs Safe

October 29, 2010

Dr. Gary Puckrein, President and CEO, National Minority Quality Forum
Opposing Views

Patient safety is a core component of our medical system. In order to assure that physicians are prescribing the best and safest treatments